The halal pharmaceutical sector is undergoing a structural shift in 2025/26, moving from a compliance-driven, import-reliant market into a capability-led, strategically positioned industry within a rapidly evolving global health order.
Muslims spent $112 billion on pharmaceutical products alone in 2024, rising 4.3% year-on-year, with a view to reach $146 billion by 2029, according to the State of the Global Islamic Economy 2025/26 Report.
Muslim markets bolstering local pharma manufacturing has been the sector’s overarching theme, expanding cross-border partnerships, and advancing traditional medicine toward mainstream, regulated integration. At the same time, demand is moving upmarket into specialty therapeutics such as oncology, as well as prevention and longevity.
Operationally, the sector is modernizing as countries institutionalize evidence-based traditional medicine through national strategies, standardized training, and hospital-based delivery models.
Healthcare systems are also expanding beyond pharmaceuticals into integrated care models, reflecting a broader diversification of the halal health ecosystem. These developments signal a transition toward more holistic, scalable, and systemized healthcare delivery across Muslim-majority markets.
In parallel, national trade and industrial policy are reshaping the competitive landscape. Governments are advancing halal pharmaceutical hub strategies, strengthening vaccine and biologics manufacturing alliances, and leveraging major health platforms to drive deals, financing, and cross-border collaboration. This reflects a growing emphasis on health sovereignty and intra-OIC trade, as countries build the production base, regulatory alignment, and partnership ecosystems needed to reduce Western import dependence.
Innovation is emerging as a key differentiator, led by Gulf hubs investing in AI-enabled drug discovery, advanced manufacturing, and halal-by-design product development. These capabilities are accelerating the shift from adoption to localized innovation and export readiness.
In 2025, Muslim-majority nations, including key GCC hubs, pushed the halal pharmaceutical value chain upmarket: scaling local manufacturing and cross-border partnerships, moving traditional medicine toward WHO-backed mainstream integration, attracting more funding and commercialization support.
Meanwhile, funding and commercialization platforms are accelerating scale-up across pharmaceuticals and biotech. Oncology therapies are expanding rapidly, supported by innovative launches and industry partnerships.
Longevity and preventive-tech are expanding the operational footprint beyond pharmaceuticals. Trade exhibitions and conventions are accelerating OIC/ Africa deal flow, investment, and collaboration.
Advanced therapeutics and high-tech research and development partnerships are strengthening the ecosystem for next-generation medicine.
Immunization funding and health security financing are also scaling long-term protection systems.